Analysts Set Ardent Health Partners, LLC (NYSE:ARDT) PT at $21.18

Ardent Health Partners, LLC (NYSE:ARDT) has been assigned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $21.18.

A number of equities research analysts have recently commented on ARDT shares. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $20.00 price target on shares of Ardent Health Partners in a report on Tuesday, December 17th. Royal Bank of Canada lowered their target price on shares of Ardent Health Partners from $23.00 to $21.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. Morgan Stanley decreased their price objective on Ardent Health Partners from $23.50 to $22.00 and set an “overweight” rating on the stock in a report on Tuesday, January 21st. Stephens reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of Ardent Health Partners in a research report on Wednesday, March 26th. Finally, Truist Financial reduced their target price on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Monday, January 6th.

Ardent Health Partners Stock Performance

ARDT stock opened at $13.78 on Tuesday. The stock’s 50 day moving average price is $14.40 and its 200 day moving average price is $16.19. The company has a quick ratio of 1.78, a current ratio of 1.91 and a debt-to-equity ratio of 0.78. Ardent Health Partners has a 1 year low of $12.87 and a 1 year high of $20.72.

Ardent Health Partners (NYSE:ARDT) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.31. The company had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.48 billion. As a group, research analysts forecast that Ardent Health Partners will post 1.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ARDT. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ardent Health Partners in the fourth quarter valued at about $27,000. Squarepoint Ops LLC boosted its holdings in Ardent Health Partners by 1.8% in the 4th quarter. Squarepoint Ops LLC now owns 101,798 shares of the company’s stock worth $1,739,000 after acquiring an additional 1,798 shares during the period. US Bancorp DE acquired a new stake in Ardent Health Partners in the fourth quarter valued at approximately $31,000. Bank of New York Mellon Corp raised its stake in shares of Ardent Health Partners by 8.2% during the fourth quarter. Bank of New York Mellon Corp now owns 25,615 shares of the company’s stock valued at $438,000 after purchasing an additional 1,941 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Ardent Health Partners by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 142,563 shares of the company’s stock worth $2,435,000 after purchasing an additional 2,127 shares in the last quarter.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.